Cite

HARVARD Citation

    Schäfer, N. et al. (2018). Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro-oncology. 20 (7), pp. 975-985. [Online]. 
  
Back to record